<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2020.1011371</article-id><article-id pub-id-type="publisher-id">ACM-38504</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20201100000_99040211.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  NET-1基因与肝细胞癌的研究进展
  Research Progress of NET-1 Gene and Hepatocellular Carcinoma
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>杨</surname><given-names>斌</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>张</surname><given-names>东宁</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>刘</surname><given-names>欢</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>孙</surname><given-names>象军</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>山东第一医科大学(山东省医学科学院)，临沂市人民医院，山东 临沂</addr-line></aff><aff id="aff3"><addr-line>青岛大学第十一临床医学院临沂市人民医院，山东 临沂</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>04</day><month>11</month><year>2020</year></pub-date><volume>10</volume><issue>11</issue><fpage>2457</fpage><lpage>2462</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    NET-1基因是新发现的肿瘤相关基因，与肝细胞癌的发生发展密切相关，研究发现NET-1通过PI3K/AKT等各种信号通路和相关分子共同促进HCC的发生发展，可作为肝细胞癌早期诊断的生物标志物和治疗靶点。本文综述近几年NET1基因在肝癌中的研究进展，揭示其潜在分子机制，具有重要临床意义。
    NET-1 gene is a newly discovered tumor-related gene, which is closely related to the occurrence and development of hepatocellular carcinoma. Research has found that NET-1 promotes the occurrence and development of HCC through various signaling pathways such as PI3K/AKT and related molecules. It can be used as an early stage of hepatocellular carcinoma, diagnostic biomarkers and therapeutic targets. This article reviews the research progress of NET-1 gene in liver cancer in recent years, reveals its potential molecular mechanism, and has important clinical significance. 
  
 
</p></abstract><kwd-group><kwd>肝细胞癌，NET-1，MIB-1，PCNA，Ki-67, Hepatocellular Carcinoma</kwd><kwd> NET-1</kwd><kwd> MIB-1</kwd><kwd> PCNA</kwd><kwd> Ki-67</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>NET-1基因是新发现的肿瘤相关基因，与肝细胞癌的发生发展密切相关，研究发现NET-1通过PI3K/AKT等各种信号通路和相关分子共同促进HCC的发生发展，可作为肝细胞癌早期诊断的生物标志物和治疗靶点。本文综述近几年NET1基因在肝癌中的研究进展，揭示其潜在分子机制，具有重要临床意义。</p></sec><sec id="s2"><title>关键词</title><p>肝细胞癌，NET-1，MIB-1，PCNA，Ki-67</p></sec><sec id="s3"><title>Research Progress of NET-1 Gene and Hepatocellular Carcinoma<sup> </sup></title><p>Bin Yang<sup>1</sup>, Dongning Zhang<sup>2</sup>, Huan Liu<sup>1</sup>, Xiangjun Sun<sup>1*</sup></p><p><sup>1</sup>Linyi People’s Hospital, Shandong First Medical University (Shandong Academy of Medical Sciences), Linyi Shandong</p><p><sup>2</sup>Linyi People’s Hospital, The Eleventh Clinical Medical College of Qingdao University, Linyi Shandong</p><p><img src="//html.hanspub.org/file/5-1571645x5_hanspub.png" /></p><p>Received: Oct. 11<sup>th</sup>, 2020; accepted: Oct. 29<sup>th</sup>, 2020; published: Nov. 5<sup>th</sup>, 2020</p><p><img src="//html.hanspub.org/file/5-1571645x6_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>NET-1 gene is a newly discovered tumor-related gene, which is closely related to the occurrence and development of hepatocellular carcinoma. Research has found that NET-1 promotes the occurrence and development of HCC through various signaling pathways such as PI3K/AKT and related molecules. It can be used as an early stage of hepatocellular carcinoma, diagnostic biomarkers and therapeutic targets. This article reviews the research progress of NET-1 gene in liver cancer in recent years, reveals its potential molecular mechanism, and has important clinical significance.</p><p>Keywords:Hepatocellular Carcinoma, NET-1, MIB-1, PCNA, Ki-67</p><disp-formula id="hanspub.38504-formula59"><graphic xlink:href="//html.hanspub.org/file/5-1571645x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2020 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/5-1571645x8_hanspub.png" /> <img src="//html.hanspub.org/file/5-1571645x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>肝细胞癌(HCC)是世界范围内常见的恶性肿瘤之一，它的特点是肿瘤生长迅速，早期无明显临床症状，发现时常为疾病中晚期，错过最佳手术时机。寻找新的生物标志物，研究其可能分子机制，尤其是肝癌侵袭转移机制，力求寻找新的药物靶点对肝细胞癌的治疗至关重要。NET-1在许多肿瘤组织中均有表达，被认为在肿瘤的诊断和治疗中具有潜在的价值。近年来NET-1基因在肝细胞癌的研究越来越多，也被看作是肝细胞癌基因治疗的潜在靶点，本文将近几年NET-1基因在肝癌中的研究进展作一综述。</p></sec><sec id="s6"><title>2. NET-1基因及蛋白</title><p>神经上皮细胞转化基因1 (Neuroepithelial cell transforming gene 1, NET-1)是Ras同源基因家族的一员，于2000年被Serru等人发现 [<xref ref-type="bibr" rid="hanspub.38504-ref1">1</xref>]，也是新发现的一种肿瘤相关基因，定位于染色体1p34.1上，其mRNA全长为1297 bp，编码序列为128~853 bp，有241个氨基酸的开放阅读框。它的蛋白质产物，最初是从神经上皮瘤细胞中分离出来的，它属于NET-X超家族，是一种四次跨膜蛋白，该家族目前包括NET-2、NET-3、NET-4、NET-5、NET-6和NET-7，其特征在于存在4个跨膜结构域，2个具有保守氨基酸残基的细胞外区域，这些都与肿瘤细胞的迁移分化、粘附增殖及信号通道相关 [<xref ref-type="bibr" rid="hanspub.38504-ref2">2</xref>]。研究发现，NET-1的异常表达与多种癌症的淋巴结转移和远处转移密切相关，包括肺癌、结直肠癌、胃癌和乳腺癌等 [<xref ref-type="bibr" rid="hanspub.38504-ref3">3</xref>] [<xref ref-type="bibr" rid="hanspub.38504-ref4">4</xref>] [<xref ref-type="bibr" rid="hanspub.38504-ref5">5</xref>]。</p></sec><sec id="s7"><title>3. NET-1与肝癌的发生、发展</title><sec id="s7_1"><title>3.1. NET-1基因促进HCC的形成</title><p>NET-1是一种特异性激活RhoA蛋白的鸟嘌呤核苷酸交换因子(GEF)，可增强癌细胞的迁移和侵袭 [<xref ref-type="bibr" rid="hanspub.38504-ref6">6</xref>]。陈莉等 [<xref ref-type="bibr" rid="hanspub.38504-ref7">7</xref>] 研究发现NET-1基因在肝癌和癌旁组织cDNA中扩增表达。相反在正常肝组织和胎儿肝组织中cDNA中未见到NET-1基因mRNA扩增表达。Shen等 [<xref ref-type="bibr" rid="hanspub.38504-ref8">8</xref>] 报道了NET-1mRNA在正常肝组织中的低水平表达，在HCC组织中高表达(P &lt; 0.05)。NET-1常在肝癌细胞的胞膜及胞质中表达，在HCC组织中NET-1的表达显著高于癌旁及正常肝脏组织，提示肝癌细胞功能的表现可能与癌细胞群体表面蛋白NET-1积聚有关，进一步说明NET-1基因能促进癌的形成，提示该蛋白可作为肝癌早期诊断的生物标志物。</p></sec><sec id="s7_2"><title>3.2. NET-1基因促进HCC的发展</title><p>NET-1蛋白作为四跨膜蛋白家族的一员，与各成员之间或与整合素、生长因子受体等细胞表面蛋白相互结合形成四跨膜蛋白网络，通过直接或间接作用于信号通道从而影响肝癌细胞的粘附、增殖、分化、转移及侵袭 [<xref ref-type="bibr" rid="hanspub.38504-ref9">9</xref>]。</p><p>Net-1A是RhoA子家族GEF，RhoA鸟嘌呤核苷酸交换因子(RhoGEF)Net-1A的Jnk依赖性磷酸化促进其胞浆积累，从而驱动RhoA活化和肌动蛋白细胞骨架重组。Jnk刺激激活的Net1A胞浆定位足以刺激非侵袭性乳腺癌细胞的细胞运动和细胞外基质的侵袭，揭示Net-1A的表达有助于癌症的转移 [<xref ref-type="bibr" rid="hanspub.38504-ref10">10</xref>]。此外，Ahmad等 [<xref ref-type="bibr" rid="hanspub.38504-ref11">11</xref>] 发现，NET-1是肿瘤抑制因子MicroRNA-22的靶点，MiR-22的过度表达可能通过下调NET-1来抑制肌动蛋白纤维的形成。即正常细胞向癌细胞的转化可能部分通过NET-1介导。Sun等 [<xref ref-type="bibr" rid="hanspub.38504-ref12">12</xref>] 通过培养肝癌细胞株MHCC97-H，检测凋亡相关蛋白Bax、cyclinD1、凋亡调节因子Bcl-2和Caspase-3的表达水平。在NET-1基因敲除后，Bax和CyclinD1表达降低，Bcl-2和caspase-3表达增加，PI3K/AKT信号通路受到抑制，研究结果表明，抑制NET-1可以通过PI3K/AKT信号通路来抑制HCC的细胞增殖，促进细胞凋亡。同时NET-1还可以激活JNK、NF-λB和WNT等信号通路 [<xref ref-type="bibr" rid="hanspub.38504-ref13">13</xref>]。Wei Zong等 [<xref ref-type="bibr" rid="hanspub.38504-ref13">13</xref>] 发现MiR-22是NET1的靶基因，CTC-497E21.4与MiR-22竞争调节NET-1的表达，且CTC-497E21.4/MiR-22-3p/NET-1形成RhoA信号通路的一部分，促进了癌症的进展。一项研究显示，肝癌组织中NET-1的表达水平与肿瘤的转移阶段有关 [<xref ref-type="bibr" rid="hanspub.38504-ref14">14</xref>]，且NET-1的表达水平与HCC的病理分级有很强的相关性 [<xref ref-type="bibr" rid="hanspub.38504-ref2">2</xref>]。</p></sec></sec><sec id="s8"><title>4. NET-1与其他分子共同作用于肝癌</title><p>NET1-1基因作为四跨膜蛋白超家族的一员，其不可能独自发挥作用，可与其他表面分子相结合形成四跨膜蛋白网络，共同调控肝癌细胞的粘附，分化，迁移和浸润等过程从而影响肝癌细胞的发生发展 [<xref ref-type="bibr" rid="hanspub.38504-ref9">9</xref>]。目前已发现的分子有：Ki-67,MIB-1,PCNA等。</p><sec id="s8_1"><title>4.1. NET-1基因与Ki-67</title><p>Ki-67是一种核抗原，主要用于判断细胞的增殖活性，表达在所有活动的细胞周期(G1、S、G2和有丝分裂期)中，但在G0期不表达，是判断肿瘤细胞增殖活性应用较广的指标。NET-1表达越强，肿瘤细胞分化越低，越易发生转移，临床分期越高，即恶性程度越高。经过大量的实验研究证明，HCC中Ki-67阳性表达为66.3%~76.3% [<xref ref-type="bibr" rid="hanspub.38504-ref15">15</xref>]，NET-1与Ki-67蛋白在肝细胞癌组织中的表达与肝细胞癌的发生发展、浸润转移和预后密切相关，NET-1与Ki-67高表达提示患者预后不良，可以作为肝细胞癌临床预测转移和判断预后的分子标记物 [<xref ref-type="bibr" rid="hanspub.38504-ref16">16</xref>]。</p></sec><sec id="s8_2"><title>4.2. NET-1基因与MIB-1</title><p>MIB-1是一种Ig G1类单克隆抗体，可以与Ki67抗原结合，检测Ki67的表达情况常用MIB-1阳性细胞为指标 [<xref ref-type="bibr" rid="hanspub.38504-ref17">17</xref>]。同时MIB-1标记指数被认为是衡量肿瘤细胞增殖水平和预测肿瘤复发的一项可靠指标，研究发现，肿瘤细胞增殖速度越快，MIB-1标记指数值越高 [<xref ref-type="bibr" rid="hanspub.38504-ref18">18</xref>]。有研究显示，分裂增殖旺盛的细胞大小形态不一，核大、胞浆少，各细胞胞浆内均有NET-1阳性反应，荧光分布似有极性呈凝块或斑点状偏在一侧，相似于细胞高尔基体处。MIB-1阳性信号见于细胞核内，呈颗粒状 [<xref ref-type="bibr" rid="hanspub.38504-ref19">19</xref>]。肝细胞癌的细胞中常同时表达NET-1和MIB-1，两者的荧光标记在同一细胞内存在良好的共定位，当核中MIB-1颗粒增多时，其胞浆内NET-1的表达荧光强度增强。NET-1表达在细胞学类型、肿瘤分级、肿瘤转移、临床分期及肝炎肝硬化背景中差异有统计学意义。肝细胞性肝癌、伴有肝炎肝硬化的肝癌中NET-1表达很高，且肿瘤中NET-1表达越强，肿瘤分化程度越低，其临床分期也越晚，也更易发生转移 [<xref ref-type="bibr" rid="hanspub.38504-ref19">19</xref>]。其结果与科学家在宫颈癌中研究的结果类似。肝癌组织中MIB-1表达强度在不同肿瘤分级、不同临床分期及转移与否差异均具有统计学意义。肿瘤分化越低，MIB-1表达越高，临床分期3-4期中MIB-1表达高于1-2期，更易转移。因此，NET-1基因与MIB-1表达在肝癌组织中呈显著正相关，与肝癌细胞增殖有关，在HCC发展中上调肿瘤细胞增殖活性，促进肝癌的发展。</p></sec><sec id="s8_3"><title>4.3. NET-1基因与PCNA</title><p>PCNA是存在于细胞核中能影响细胞增殖的一种蛋白质，它可作为细胞增殖的一个指标，已证实可在多种实体癌、炎性增殖乃至正常增殖组织的细胞核中表达，并被认为PCNA阳性率与肿瘤的分级、分期、疗效和预后有一定关系 [<xref ref-type="bibr" rid="hanspub.38504-ref20">20</xref>]。</p><p>近年来研究结果显示，肝细胞癌增殖活性的改变在肝癌形成过程中的作用尤为重要，有科学家对肝癌发生不同时期肝组织病变中肝细胞增殖和凋亡进行了研究，认为在肝癌形成的各个阶段，凋亡和增殖均有不同程度的增加，但其增加程度不同，细胞的增殖速度高于凋亡速度，细胞数量净增加，增殖和凋亡的平衡打破最终导致肝癌的发生。PCNA作为一种肿瘤的标记物，可反映肿瘤细胞的代谢以及DNA和RNA的合成状态，其阳性表达与肿瘤细胞的分化和肿瘤组织类型与关，肝癌组织分化越差，PCNA标记指数越高。经过研究表明，NET-1和PCNA在肝癌组织中的表达水平呈正相关 [<xref ref-type="bibr" rid="hanspub.38504-ref21">21</xref>]，表明PCNA和NET-1可能与肝细胞癌的增殖密切相关。</p></sec></sec><sec id="s9"><title>5. NET-1作为治疗性靶基因的相关研究</title><p>肝癌的治疗方法会因为疾病的程度不同而不同，包括小的局部肿瘤的外科手术切除，还有肝移植，非外科侵入性治疗，如射频消融术(RFA)和经动脉化疗栓塞(TACE)，以及更先进的新生物疗法。随着生物技术的发展，基因治疗已成为治疗癌症的新策略。与传统的手术治疗方法相比，基因治疗可准确有效的杀死肿瘤细胞，副作用少 [<xref ref-type="bibr" rid="hanspub.38504-ref22">22</xref>]。靶向治疗通过沉默与肿瘤细胞增殖或转移相关的基因，作为基因治疗的一种方法，在肝癌治疗中显示出巨大的潜力。高选择性、序列特异性和高效性使靶向治疗技术适用于治疗肝癌，副作用小 [<xref ref-type="bibr" rid="hanspub.38504-ref23">23</xref>]。而靶向治疗的关键是要找到肝癌的特异性基因。NET-1基因可能通过与位于分泌细胞器膜上的其他跨膜和细胞溶质蛋白相互作用来调节癌细胞的增殖，并在细胞质中发挥作用。Ye等 [<xref ref-type="bibr" rid="hanspub.38504-ref24">24</xref>] 发现，敲低NET-1基因可使HCC癌细胞的迁移，侵袭和转移分别减少44%，65%和77%。Zhang等 [<xref ref-type="bibr" rid="hanspub.38504-ref25">25</xref>] 研究发现NET-1 siRNA可能通过下调VEGF而诱导体内宫颈鳞癌血管生成和肿瘤生长。VEGF途径可能代表了大多数癌症的抗血管生成治疗。抑制NET-1表达导致SiHa细胞VEGF表达下调。越来越多的研究表明，以NET-1基因为靶点的SiRNA技术可以有效抑制NET-1基因在肝癌中的表达和功能，NET-1可能是肝癌的治疗靶点，有希望通过NET-1基因靶向治疗肝细胞癌。</p></sec><sec id="s10"><title>6. 小结与展望</title><p>NET-1在许多肿瘤组织中均有表达，被认为在肿瘤的诊断和治疗中具有潜在的价值。近年来，越来越多的研究发现NET-1通过PI3K/AKT等各种信号通路促进HCC的发生发展，同时，NET-1通过与MIB-1，PCNA，Ki-67，MicroRNA-630等多种分子共同作用于HCC，NET-1可能是肝癌的治疗靶点。目前，由于HCC基因治疗的研究有限看，尚需更多NET-1的基础及临床试验探索，力求早期应用于HCC的治疗上。</p></sec><sec id="s11"><title>基金项目</title><p>山东省重点研发计划，项目编号：GSF1118191。</p></sec><sec id="s12"><title>文章引用</title><p>杨 斌,张东宁,刘 欢,孙象军. NET-1基因与肝细胞癌的研究进展Research Progress of NET-1 Gene and Hepatocellular Carcinoma[J]. 临床医学进展, 2020, 10(11): 2457-2462. https://doi.org/10.12677/ACM.2020.1011371</p></sec><sec id="s13"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.38504-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Serru, V., Dessen, P., Boucheix, C., et al. (2000) Sequence and Expression of Seven New Tetraspans. Biochimica et Biophysica Acta, 1478, 159-163. &lt;br&gt;https://doi.org/10.1016/S0167-4838(00)00022-4</mixed-citation></ref><ref id="hanspub.38504-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Chen, L., Wang, Z., Zhan, X., et al. (2007) Association of NET-1 Gene Expression with Human Hepatocellular Carcinoma. International Journal of Surgical Pathology, 15, 346-353. &lt;br&gt;https://doi.org/10.1177/1066896907306083</mixed-citation></ref><ref id="hanspub.38504-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Gabitova, G. and Burke, N.J. (2014) Improving Healthcare Empowerment through Breast Cancer Patient Navigation: A Mixed Methods Evaluation in a Safety-Net Setting. BMC Health Services Research, 14, Article No. 407.  
&lt;br&gt;https://doi.org/10.1186/1472-6963-14-407</mixed-citation></ref><ref id="hanspub.38504-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Wheelock, A.E., Bock, M.A., Martin, E.L., et al. (2015) SIS. NET: A Randomized Controlled Trial Evaluating a Web-Based System for Symptom Management after Treatment of Breast Cancer. Cancer, 121, 893-899.  
&lt;br&gt;https://doi.org/10.1002/cncr.29088</mixed-citation></ref><ref id="hanspub.38504-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Fang, L., Zhu, J., Ma, Y., et al. (2015) Neuroepithelial Transforming Gene 1 Functions as a Potential Prognostic Marker for Patients with Non-Small Cell Lung Cancer. Molecular Medicine Reports, 12, 7439-7446.  
&lt;br&gt;https://doi.org/10.3892/mmr.2015.4385</mixed-citation></ref><ref id="hanspub.38504-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Alberts, A.S. and Treisman, R. (1998) Activation of RhoA and SAPK/JNK Signalling Pathways by the RhoA-Specific Exchange Factor mNET1. The EMBO Journal, 17, 4075-4085. &lt;br&gt;https://doi.org/10.1093/emboj/17.14.4075</mixed-citation></ref><ref id="hanspub.38504-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">陈莉, 沈爱国, 王桂兰, 等. 肝癌及相关组织中NET-1基因与蛋白的表达[J]. 癌症, 2006, 25(3): 320-325.</mixed-citation></ref><ref id="hanspub.38504-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Shen, S., Li, K., Zhu, N., et al. (2008) Expression and Clinical Significance of NET-1 and PCNA in Hepatocellular Carcinoma. Medical Oncology (Northwood, London, England), 25, 341-345.  
&lt;br&gt;https://doi.org/10.1007/s12032-008-9042-6</mixed-citation></ref><ref id="hanspub.38504-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">何磊. 四跨膜蛋白在肝癌中的作用[J]. 中国肿瘤临床, 2011, 38(18): 1175-1178.</mixed-citation></ref><ref id="hanspub.38504-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Ulu, A. and Frost, J.A. (2018) Regulation of RhoA Activation and Cell Motility by c-Jun N-terminal Kinases and Net1. Small GTPases, 11, 385-391. &lt;br&gt;https://doi.org/10.1080/21541248.2018.1536638</mixed-citation></ref><ref id="hanspub.38504-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Ahmad, H.M., Muiwo, P., Ramachandran, S.S., et al. (2014) miR-22 Regulates Expression of Oncogenic Neuro-Epi- thelial Transforming Gene 1, NET1. The FEBS Journal, 281, 3904-3919. &lt;br&gt;https://doi.org/10.1111/febs.12926</mixed-citation></ref><ref id="hanspub.38504-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Sun, X., Wang, M., Zhang, F., et al. (2019) Inhibition of NET-1 Suppresses Proliferation and Promotes Apoptosis of Hepatocellular Carcinoma Cells by Activating the PI3K/AKT Signaling Pathway. Experimental and Therapeutic Medicine, 17, 2334-2340. &lt;br&gt;https://doi.org/10.3892/etm.2019.7211</mixed-citation></ref><ref id="hanspub.38504-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Zong, W., Feng, W., Jiang, Y., et al. (2020) LncRNA CTC-497E21.4 Promotes the Progression of Gastric Cancer via Modulating miR-22/NET1 Axis through RhoA Signaling Pathway. Gastric Cancer, 23, 228-240.  
&lt;br&gt;https://doi.org/10.1007/s10120-019-00998-w</mixed-citation></ref><ref id="hanspub.38504-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Sun, C.K., Chua, M.S., He, J., et al. (2011) Suppression of Glypican 3 Inhibits Growth of Hepatocellular Carcinoma Cells through Up-Regulation of TGF-beta2. Neoplasia, 13, 735-747. &lt;br&gt;https://doi.org/10.1593/neo.11664</mixed-citation></ref><ref id="hanspub.38504-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">孟秀香, 刘丹丹, 聂慧玲, 等. Bmi-1与Ki-67在肺腺癌中的表达及其临床意义[J]. 中国老年学杂志, 2012, 32(7): 1381-1383.</mixed-citation></ref><ref id="hanspub.38504-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">刘晓丽, 马礼鸿, 王凯. NET-1、Ki-67在肺腺癌组织中的表达及意义[J]. 中国老年学杂志, 2012, 32(23): 5297-5298.</mixed-citation></ref><ref id="hanspub.38504-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">马晓欣, 李晓晗, 李娜, 等. 细胞核增殖相关抗原Ki67在子宫内膜病变中的表达[J]. 中国肿瘤临床, 2005, 32(19): 1104-1106.</mixed-citation></ref><ref id="hanspub.38504-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Abry, E., Thomassen, I.O., Salvesen, O.O., et al. (2010) The Significance of Ki-67/MIB-1 Labeling Index in Human Meningiomas: A Literature Study. Pathology Research and Practice, 206, 810-815.  
&lt;br&gt;https://doi.org/10.1016/j.prp.2010.09.002</mixed-citation></ref><ref id="hanspub.38504-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">李杏玉, 陈莉. NET-1和MIB-1在肝癌中的表达及意义[J]. 天津医药, 2009, 37(11): 917-919.</mixed-citation></ref><ref id="hanspub.38504-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Pizem, J., Marolt, V.F., Luzar, B., et al. (2001) Proliferative and Apoptotic Activity in Hepatocellular Carcinoma and Surrounding Non-Neoplastic Liver Tissue. Pflügers Archiv, 442, R174-R176. &lt;br&gt;https://doi.org/10.1007/s004240100014</mixed-citation></ref><ref id="hanspub.38504-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">朱能, 沈世强, 夏悦明, 等. NET-1、PCNA在肝细胞癌中的表达及临床意义[J]. 中华肝胆外科杂志, 2009, 15(4): 262-265.</mixed-citation></ref><ref id="hanspub.38504-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Liang, X., Wu, B., Shang, H., et al. (2018) VTIQ Evaluates Antitumor Effects of NET-1 siRNA by UTMD in HCC Xenograft Models. Oncology Letters, 16, 2893-2902. &lt;br&gt;https://doi.org/10.3892/ol.2018.8994</mixed-citation></ref><ref id="hanspub.38504-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Wang, G.L., Chen, L., Wei, Y.Z., et al. (2012) The Effect of NET-1 on the Proliferation, Migration and Endocytosis of the SMMC-7721 HCC Cell Line. Oncology Reports, 27, 1944-1952. &lt;br&gt;https://doi.org/10.3892/or.2012.1698</mixed-citation></ref><ref id="hanspub.38504-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Ye, K., Chang, S., Li, J., et al. (2014) A Functional and Protein-Protein Interaction Analysis of Neuroepithelial Cell Transforming Gene 1 in Hepatocellular Carcinoma. Tumor Biology, 35, 11219-11227.  
&lt;br&gt;https://doi.org/10.1007/s13277-014-2454-3</mixed-citation></ref><ref id="hanspub.38504-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Zhang, Y., Xia, P., Zhang, W., et al. (2017) Short Interfering RNA Targeting Net1 Reduces the Angiogenesis and Tumor Growth of in Vivo Cervical Squamous Cell Carcinoma through VEGF Down-Regulation. Human Pathology, 65, 113-122. &lt;br&gt;https://doi.org/10.1016/j.humpath.2017.04.021</mixed-citation></ref></ref-list></back></article>